PeptideStack
5.2kquestions
20kanswers
220users

orforglipron

Page 5 of 10 · 219 questions tagged orforglipron.

219 questions · sorted by votes · page 5 of 10

20 votes 5 answers30k views
What does 99.4% purity on a C4 column actually tell me about an orforglipron vial?

Conditions: 99.4% · a C4 column · orforglipron. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single…

hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

503 questions
purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by harriet_lonsdale 35k · 19 months ago
20 votes4 answers22k views
Is HbA1c a better monitoring choice than eGFR on orforglipron?

Concretely: HbA1c · eGFR · orforglipron. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to know that, so I can…

bloodwork
bloodwork

Laboratory monitoring: which panels are worth ordering, sensible intervals, reference-range versus optimal-range arguments, and how to read a…

296 questions
kidney-function
kidney-function

eGFR, creatinine, cystatin C and albuminuria: the acute haemodynamic dip that is not injury, the renal outcome data from the FLOW programme, and…

141 questions
lipids
lipids

Lipid response on treatment: triglycerides, LDL-C, non-HDL-C, ApoB and Lp(a), which of them move with weight loss, and why a fasting panel drawn…

139 questions
a1c
a1c

Glycated haemoglobin as a ninety-day glycaemic average: what a change of half a point means, why it lags, and the conditions under which it…

122 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by mz_4113 101k · 18 months ago
20 votes 3 answers10k views
Does hydrolysis dominate for orforglipron held at 40 °C?

Details up front: hydrolysis · orforglipron · 40 °C. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

503 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by Dr_Ravi_Selvarajah 35k · 10 months ago
20 votes 3 answers8.2k views
Is 96.8% a realistic purity ceiling for orforglipron given its chain length?

Details up front: 96.8% · orforglipron. This should be a straightforward calculation and I keep getting two different answers. The numbers are arbitrary; the method…

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

503 questions
peptide-mapping
peptide-mapping

Enzymatic digestion followed by LC-MS/MS to confirm sequence rather than just mass. The method that catches a scrambled sequence or a D-amino-acid…

103 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by bridget_nyathi 12k · 35 days ago
20 votes0 answers7.6k views
My orforglipron vial sat at 2–8 °C for forty-two days — is testing worth it before use?

What I am working with: orforglipron · 2–8 °C · forty-two days. I am trying to build something sustainable rather than something thorough that I will abandon. I have…

cold-chain
cold-chain

Keeping material within a temperature window from manufacture to use: phase-change packs versus dry ice, thermal mass, transit-lane temperature…

578 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by u100_marks 52k · 9 months ago
20 votes0 answers5k views
My orforglipron vial sat at room temperature for forty-two days — is testing worth it before use?

Concretely: orforglipron · room temperature · forty-two days. I am trying to build something sustainable rather than something thorough that I will abandon. I have…

cold-chain
cold-chain

Keeping material within a temperature window from manufacture to use: phase-change packs versus dry ice, thermal mass, transit-lane temperature…

578 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by bridget_nyathi 12k · 12 months ago
19 votes 5 answers23k views
Can I reconstitute orforglipron at 3.33 mg/mL and still measure a small dose accurately?

Stated plainly: orforglipron · 3.33 mg/mL. I am trying to build something sustainable rather than something thorough that I will abandon. I have already decided the…

diluent-volume
diluent-volume

Choosing how much diluent to add, which is really a question about what you want your measurement resolution to be. Larger volumes buy you…

295 questions
insulin-syringe
insulin-syringe

U-100 and U-40 insulin syringes as measuring instruments. A U-100 syringe is graduated in insulin units where 100 units equals 1 mL, so one unit…

244 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by coring_risk 27k · 11 months ago
19 votes5 answers17k views
Does albumin-to-creatinine ratio tell me anything about hepatic fat on orforglipron?

What I have: albumin-to-creatinine ratio · orforglipron. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring…

liver-enzymes
liver-enzymes

ALT, AST, GGT and ALP: what they do and do not indicate about hepatic fat, why enzymes are a poor surrogate for histology, and where non-invasive…

91 questions
mash
mash

Metabolic dysfunction-associated steatohepatitis: histological endpoints, resolution without worsening fibrosis, fibrosis improvement by stage,…

56 questions
bloodwork
bloodwork

Laboratory monitoring: which panels are worth ordering, sensible intervals, reference-range versus optimal-range arguments, and how to read a…

296 questions
kidney-function
kidney-function

eGFR, creatinine, cystatin C and albuminuria: the acute haemodynamic dip that is not injury, the renal outcome data from the FLOW programme, and…

141 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by rhian_prydderch 23k · 7 months ago
19 votes2 answers13k views
Can I reconstitute orforglipron at 8 mg/mL and still measure a small dose accurately?

What I am working with: orforglipron · 8 mg/mL. I would like to set this up properly once, rather than adjust it repeatedly. My budget is real but not tight, and my…

diluent-volume
diluent-volume

Choosing how much diluent to add, which is really a question about what you want your measurement resolution to be. Larger volumes buy you…

295 questions
insulin-syringe
insulin-syringe

U-100 and U-40 insulin syringes as measuring instruments. A U-100 syringe is graduated in insulin units where 100 units equals 1 mL, so one unit…

244 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by plunger_stop 13k · 6 months ago
19 votes 1 answer10k views
Would you accept 96.4% on orforglipron from QYB without a content assay?

Numbers first: 96.4% · orforglipron · QYB. This is a planning question. I know what my options are; I do not know how to weigh them. What I want is the minimum viable…

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

476 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

454 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by rukhsana_iqbal 17k · 7 months ago
19 votes 5 answers8.3k views
How comparable are orforglipron and tirzepatide on the evidence available?

Details up front: orforglipron · tirzepatide. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I can obtain either…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by gel_pack_warm 13k · 7 months ago
19 votes 3 answers6k views
Why did my ferritin move after four weeks on orforglipron?

Conditions: ferritin · four weeks · orforglipron. I think I have a problem. I am not yet sure whether it is a real problem or a measurement artefact. I want to know…

bloodwork
bloodwork

Laboratory monitoring: which panels are worth ordering, sensible intervals, reference-range versus optimal-range arguments, and how to read a…

296 questions
kidney-function
kidney-function

eGFR, creatinine, cystatin C and albuminuria: the acute haemodynamic dip that is not injury, the renal outcome data from the FLOW programme, and…

141 questions
lipids
lipids

Lipid response on treatment: triglycerides, LDL-C, non-HDL-C, ApoB and Lp(a), which of them move with weight loss, and why a fasting panel drawn…

139 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by helena_vidmar 8.5k · 2 months ago
19 votes 5 answers5k views
Is an 18G drawing needle the right choice for drawing orforglipron at 8 mg/mL?

Details up front: an 18G drawing needle · orforglipron · 8 mg/mL. I have used one of these for a while and I am considering switching, which requires a reason. What I…

needle-gauge
needle-gauge

Gauge and length selection, the trade-off between draw time and tissue trauma, coring risk with larger-bore needles, and why a fixed-needle…

91 questions
injection-technique
injection-technique

Technique questions: angle, pinch versus flat, aspiration, injection speed, air bubbles, and the handling steps that determine whether you deliver…

96 questions
dead-space
dead-space

The volume trapped in the syringe hub and needle after the plunger bottoms out. It is small in absolute terms and large as a fraction of a small…

117 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by lipid_panel_q 36k · 6 months ago
19 votes 5 answers3.7k views
What interval makes sense for repeating TSH on orforglipron?

The specifics, since they change the answer: TSH · orforglipron. I would rather over-plan the first cycle and simplify later. I am prepared to do the work if someone…

bloodwork
bloodwork

Laboratory monitoring: which panels are worth ordering, sensible intervals, reference-range versus optimal-range arguments, and how to read a…

296 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
a1c
a1c

Glycated haemoglobin as a ninety-day glycaemic average: what a change of half a point means, why it lags, and the conditions under which it…

122 questions
thyroid
thyroid

Thyroid questions: the rodent C-cell findings behind the labelled warning, human calcitonin data, TSH drift during weight loss, and the…

23 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by cal_hennessy 17k · 15 days ago
18 votes5 answers42k views
Does a phase-change pack hold an orforglipron shipment for three days in transit?

Concretely: orforglipron · three days. The units are where I keep going wrong, so please be explicit about them. I have sanity-checked the order of magnitude and it…

cold-chain
cold-chain

Keeping material within a temperature window from manufacture to use: phase-change packs versus dry ice, thermal mass, transit-lane temperature…

578 questions
international-shipping
international-shipping

Cross-border movement of research material: transit lanes and their thermal profiles, tracked versus untracked, declaration accuracy, and what…

471 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by a_lindgren 58k · 2.1 years ago
18 votes 5 answers28k views
Is orforglipron at 5 mg/mL stable enough for sixteen weeks of multi-withdrawal use?

Stated plainly: orforglipron · 5 mg/mL · sixteen weeks. This is asserted often enough that I assumed it was established, and then I went looking for the source. I…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
bacteriostatic-water
bacteriostatic-water

Water for injection containing roughly 0.9 per cent benzyl alcohol as a bacteriostatic agent. It suppresses growth in a multiple-withdrawal vial;…

149 questions
shelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

327 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by kwn_analytical 147k · 23 months ago
18 votes 5 answers21k views
What counter-ion should I expect on a KP orforglipron lot?

Details up front: KP · orforglipron. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…

acetate-content
acetate-content

Counter-ion content, most often acetate or trifluoroacetate, and why it matters: the counter-ion and residual water are part of the gross mass you…

88 questions
purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

476 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by tri_gly_ala 24k · 14 months ago
18 votes 4 answers17k views
Why did my HbA1c move after twelve weeks on orforglipron?

Concretely: HbA1c · twelve weeks · orforglipron. I have two candidate explanations and no way to distinguish them. The same procedure has worked without incident…

bloodwork
bloodwork

Laboratory monitoring: which panels are worth ordering, sensible intervals, reference-range versus optimal-range arguments, and how to read a…

296 questions
kidney-function
kidney-function

eGFR, creatinine, cystatin C and albuminuria: the acute haemodynamic dip that is not injury, the renal outcome data from the FLOW programme, and…

141 questions
lipids
lipids

Lipid response on treatment: triglycerides, LDL-C, non-HDL-C, ApoB and Lp(a), which of them move with weight loss, and why a fasting panel drawn…

139 questions
a1c
a1c

Glycated haemoglobin as a ninety-day glycaemic average: what a change of half a point means, why it lags, and the conditions under which it…

122 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by noor_alhassan 11k · 16 months ago
18 votes 4 answers15k views
What does the mechanism of orforglipron predict that ATTAIN-1 did not test?

Stated plainly: orforglipron · ATTAIN-1. The empirical answer seems settled. The explanation does not. If the honest answer is that nobody knows, I would rather hear…

glp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

132 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gip-receptor
gip-receptor

GIP receptor pharmacology, and the still-unsettled question of whether agonism or antagonism at GIPR is the metabolically useful direction.…

34 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by jo_vandeberg 23k · 6 months ago
18 votes 5 answers14k views
Does early satiety at week two of orforglipron usually resolve without a dose change?

The case in front of me: early satiety · two · orforglipron. I am trying to do this correctly the first time rather than learn it by getting it wrong. I have already…

gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by ravenna_pace 14k · 7 months ago
18 votes 5 answers13k views
Is orforglipron comparable to a peptide agonist on any axis?

I would like to know how much of this is established and how much is a reasonable story. I want to know what the trade-off actually is rather than which option is…

orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
asked by Dr_Lena_Ostrowska 38k · 10 months ago
18 votes 5 answers8.9k views
Is orforglipron at 8 mg/mL stable enough for sixteen weeks of multi-withdrawal use?

What I am working with: orforglipron · 8 mg/mL · sixteen weeks. This is asserted often enough that I assumed it was established, and then I went looking for the…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
bacteriostatic-water
bacteriostatic-water

Water for injection containing roughly 0.9 per cent benzyl alcohol as a bacteriostatic agent. It suppresses growth in a multiple-withdrawal vial;…

149 questions
shelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

327 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by tobias_reint 20k · 7 months ago
18 votes0 answers8.4k views
What happens to orforglipron after two weeks at 30 °C in solution?

Setup, so nobody has to ask: orforglipron · two weeks · 30 °C. The empirical answer seems settled. The explanation does not. If the honest answer is that nobody…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
shelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

327 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by olu_babatunde 6.2k · 22 months ago
18 votes 5 answers8.3k views
Is an 18G drawing needle the right choice for drawing orforglipron at 2 mg/mL?

Numbers first: an 18G drawing needle · orforglipron · 2 mg/mL. I want to know what the trade-off actually is rather than which option is fashionable. I would rather…

needle-gauge
needle-gauge

Gauge and length selection, the trade-off between draw time and tissue trauma, coring risk with larger-bore needles, and why a fixed-needle…

91 questions
injection-technique
injection-technique

Technique questions: angle, pinch versus flat, aspiration, injection speed, air bubbles, and the handling steps that determine whether you deliver…

96 questions
dead-space
dead-space

The volume trapped in the syringe hub and needle after the plunger bottoms out. It is small in absolute terms and large as a fraction of a small…

117 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by lukas_sedlacek 16k · 3 months ago